3-acetoxypiperidine | 89122-73-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 3-acetoxypiperidine
• 英文别名: Piperidin-3-yl acetate
• CAS: 89122-73-6
• 化学式: C₇H₁₃NO₂
• mdl: MFCD19216612
• 分子量: 143.186
• InChiKey: XEANSFYKBWJPTR-UHFFFAOYSA-N

物化性质

• 沸点：
  193.8±33.0 °C(Predicted)
• 密度：
  1.04±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.857
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-acetoxypiperidine 在 羟胺 、 potassium carbonate 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 sodium hydroxide 作用下， 以 四氢呋喃 、 乙醇 、 水 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 反应 38.0h， 生成 N-[5-[3-(3-羟基-1-哌啶基)-1,2,4-恶二唑-5-基]-4-甲基-2-噻唑基]乙酰胺
  参考文献：
  名称：

  Discovery of N-{5-[3-(3-hydroxypiperidin-1-yl)-1,2,4-oxadiazol-5-yl]-4-methyl-1,3-thiazol-2-yl}acetamide (TASP0415914) as an orally potent phosphoinositide 3-kinase γ inhibitor for the treatment of inflammatory diseases

  摘要：

  Class I phosphoinositide 3-kinases (PI3Ks), particularly PI3K gamma, have become attractive drug targets for inflammatory and autoimmune disorders such as rheumatoid arthritis. Herein, we describe the synthesis and the structure-activity relationships (SAR) of a series of 2-amino-5-oxadiazolyl thiazoles, culminating in the identification of 8j (TASP0415914), an orally potent inhibitor of phosphoinositide 3-kinase gamma (PI3K gamma). TASP0415914 demonstrated good potency in a cell-based assay and, furthermore, exhibited in vivo efficacy in a collagen induced arthritis (CIA) model in mice after oral administration. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2013.10.042
• 作为产物：
  描述：

  N-BOC-3-羟基哌啶 在 吡啶 、 盐酸 作用下， 以 乙酸乙酯 为溶剂， 反应 28.0h， 生成 3-acetoxypiperidine
  参考文献：
  名称：

  Discovery of N-{5-[3-(3-hydroxypiperidin-1-yl)-1,2,4-oxadiazol-5-yl]-4-methyl-1,3-thiazol-2-yl}acetamide (TASP0415914) as an orally potent phosphoinositide 3-kinase γ inhibitor for the treatment of inflammatory diseases

  摘要：

  Class I phosphoinositide 3-kinases (PI3Ks), particularly PI3K gamma, have become attractive drug targets for inflammatory and autoimmune disorders such as rheumatoid arthritis. Herein, we describe the synthesis and the structure-activity relationships (SAR) of a series of 2-amino-5-oxadiazolyl thiazoles, culminating in the identification of 8j (TASP0415914), an orally potent inhibitor of phosphoinositide 3-kinase gamma (PI3K gamma). TASP0415914 demonstrated good potency in a cell-based assay and, furthermore, exhibited in vivo efficacy in a collagen induced arthritis (CIA) model in mice after oral administration. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2013.10.042

文献信息

• Substituted (.omega.-aminoalkoxy)stilbene derivatives as a new class of anticonvulsants
  作者：Ryoji Kikumoto、Akihiro Tobe、Harukazu Fukami、Kunihiro Ninomiya、Mitsuo Egawa

  DOI：10.1021/jm00371a015

  日期：1984.5

  (omega- aminoalkoxy )stilbene derivatives has been synthesized and screened for anticonvulsant activity. The effect of structural modification of these molecules on the activities has been systematically examined. Potent anticonvulsant activity was displayed by 2-[4-(4-methyl-1 piperazinyl)butoxy]stilbene (20) and some 2-[4-(3-alkoxy-1-piperidino)butoxy]stilbene derivatives (21, 37, 38, and 40), as determined

  已合成了一系列取代的（ω-氨基烷氧基）二苯乙烯衍生物，并筛选了其抗惊厥活性。已经系统地检查了这些分子的结构修饰对活性的影响。2- [4-（4-甲基-1哌嗪基）丁氧基] sti烯（20）和某些2- [4-（3-烷氧基-1-哌啶基）丁氧基] sti烯衍生物（21，37， 38和40），通过最大电击惊厥（MES）和戊四氮诱发的小鼠惊厥试验确定。在大鼠的进一步药理试验中，化合物21的抗MES活性比二苯乙内酰脲和卡马西平更强，其治疗指数优于两种抗癫痫药。
• Steric, Electronic and Conformational Synergistic Effects in the Gold(I)‐catalyzed α <i>‐</i> C−H Bond Functionalization of Tertiary Amines**
  作者：David F. León Rayo、Ali Mansour、Wenbin Wu、Benjamin N. Bhawal、Fabien Gagosz

  DOI：10.1002/anie.202212893

  日期：2023.1.16

  gold-catalyzed α-C−H bond functionalization of tertiary amine was achieved via the intermediacy of a reactive α-imino gold carbene. The use of a malonate group exerting electronic, steric and conformational synergistic effects was key to the success of the transformation. The tetrahydro-γ-carboline products could be subsequently oxidized to access structural motifs found in bioactive natural products.

  具有挑战性的金催化的叔胺 α-C-H 键功能化是通过反应性 α-亚氨基金卡宾的中介实现的。使用发挥电子、空间和构象协同作用的丙二酸基团是转化成功的关键。四氢-γ-咔啉产物随后可以被氧化以获得生物活性天然产物中发现的结构基序。
• 3-AMINOPIPERIDINE DERIVATIVES AS INTEGRIN $g(a)v$g(b)3 ANTAGONISTS
  申请人：Meiji Seika Kaisha, Ltd.

  公开号：EP1227083A1

  公开（公告）日：2002-07-31

  An object of the present invention is to provide novel derivatives having integrin αvβ3 antagonistic activity wherein a basic atomic group has been attached to the 3-position of a piperidine ring either directly or through various atomic groups. The derivatives according to the present invention are compounds represented by formula (I) or pharmaceutically acceptable salts or solvates thereof, which are useful for the treatment or prevention of cardiovascular diseases, angiogenesis-related diseases, cerebrovascular diseases, cancers and metastasis thereof, immunological diseases, osteopathy and other diseases: wherein A represents an optionally substituted heterocyclic group containing at least one nitrogen atom, a bicylic group or the like; D represents a bond, >NR4, >CR5R6, O, S, or -NR4-CR5R6-; Z represents CH or N; R7 and R8 represent hydroxyl, alkyl or the like; Q represents >C=O or the like; R9 represents hydrogen, alkyl or the like; J represents a bond or alkylene; R10 represents optionally substituted hydroxyl, amino or the like; R11 represents hydrogen, alkyl or the like; m is 0 to 5; n is 0 to 4; p is 3 or 4; and q is 0 to 3.

  本发明的目的是提供具有整合素αvβ3拮抗活性的新型衍生物，其中碱性原子团直接或通过各种原子团连接到哌啶环的3位。根据本发明的衍生物是式 (I) 所代表的化合物或其药学上可接受的盐或溶液，可用于治疗或预防心血管疾病、血管生成相关疾病、脑血管疾病、癌症及其转移、免疫疾病、骨病和其他疾病： 其中，A 代表含有至少一个氮原子的任选取代杂环基团、双环基团或类似基团；D 代表键、>NR4、>CR5R6、O、S 或 -NR4-CR5R6-；Z 代表 CH 或 N；R7 和 R8 代表羟基、烷基或类似基团；Q 代表 >C=O 或类似物；R9 代表氢、烷基或类似物；J 代表键或亚烷基；R10 代表任选取代的羟基、氨基或类似物；R11 代表氢、烷基或类似物；m 为 0 至 5；n 为 0 至 4；p 为 3 或 4；q 为 0 至 3。
• PROCESS FOR PREPARING HETEROCYCLIC COMPOUNDS
  申请人：ELI LILLY AND COMPANY

  公开号：EP0983269A1

  公开（公告）日：2000-03-08
• EP0983269A4
  申请人：——

  公开号：EP0983269A4

  公开（公告）日：2001-06-27